Biblio

63 Ergebnisse exportiert:
Autor Titel Typ [ Jahr(Asc)]
Filterkriterien: Anfangsbuchstabe Des Nachnamens is J  [Alle Filter deaktivieren]
2020
Guicciardo E, Lehti TA, Korhonen A, Salvén P, Lehti K, Jeltsch M, u. a.. Lymphatics and the eye. [Finnish]. Duodecim Lääketieteellinen Aikakauskirja. 2020;:accepted for publication.
2013
Krebs R, Jeltsch M. Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D. Lymphologie in Forschung und Praxis. 2013;17(1):30-37.
Krebs R, Jeltsch M. Die lymphangiogenic growth factors VEGF-C and VEGF-D. Part 2: The role of VEGF-C and VEGF-D in diseases of the lymphatic system. [bilingual: English, German]. Lymphologie in Forschung und Praxis [Internet]. 2013;17(2):96 - 104. http://jeltsch.org/sites/jeltsch.org/files/JeltschMichael_Lymphforsch2013_96.pdfPDF Icon Krebs & Jeltsch (2013): The lymphangiogenic growth factors VEGF-C and VEGF-D. Part 2: The role of VEGF-C and VEGF-D in diseas... (3.88 MB)PDF Icon Krebs & Jeltsch (2013): Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D. Teil 2. Die Rolle von VEGF-C und VEGF-D bei ... (2.6 MB)
Krebs R, Jeltsch M. The lymphangiogenic growth factors VEGF-C and VEGF-D. Part 1: Basic principles and embryonic development. [bilingual: English, German]. Lymphologie in Forschung und Praxis [Internet]. 2013;17(1):30 - 37. http://jeltsch.org/sites/jeltsch.org/files/JeltschMichael_Lymphforsch2013_30.pdfPDF Icon Krebs & Jeltsch (2013): The lymphangiogenic growth factors VEGF-C and VEGF-D. Part 1: Fundamentals and embryonic development. (2.08 MB)PDF Icon Krebs & Jeltsch (2013): Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D. Teil 1. Grundlagen und Embryonalentwicklung. (1.82 MB)
2010
Saharinen P, Helotera H, Miettinen J, Norrmen C, D'Amico G, Jeltsch M, u. a.. Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development. Genes Dev [Internet]. 2010;24(9):875 - 80. http://view.ncbi.nlm.nih.gov/pubmed/20439428PDF Icon Pipsa Saharinen et al., Genes & Development 2010 (1.2 MB)PDF Icon Pipsa Saharinen et al., Genes & Development 2010, supplement (9.15 MB)
Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, u. a.. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043PDF Icon Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB)PDF Icon Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB)
Leppänen V-M, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, u. a.. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2010;107(6):2425 - 30. http://view.ncbi.nlm.nih.gov/pubmed/20145116PDF Icon Veli-Matti Leppänen et al. PNAS 2010 (1 MB)PDF Icon Veli-Matti Leppänen et al. PNAS 2010, supporting information (2.23 MB)
Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, u. a.. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841PDF Icon Imke Albrecht et al., PLoS One 2010 (3.37 MB)
Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, u. a.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974PDF Icon Maija Bry et al., Circulation 2010 (2.23 MB)PDF Icon Maija Bry et al., Circulation 2010, supplement (17.77 MB)
2008
Karpanen T, Bry M, Ollila HM, Seppänen-Laakso T, Liimatta E, Leskinen H, u. a.. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res [Internet]. 2008;103(9):1018 - 26. http://view.ncbi.nlm.nih.gov/pubmed/18757827PDF Icon Terhi Kärpänen et al., Circulation Research 2008 (898.27 KB)PDF Icon Terhi Kärpänen et al., Circulation Research 2008, supplement (1.56 MB)
Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, u. a.. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol [Internet]. 2008;28(9):1614 - 20. http://view.ncbi.nlm.nih.gov/pubmed/18511699PDF Icon Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008 (738.26 KB)PDF Icon Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008, data supplement (1012.6 KB)
Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, u. a.. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol [Internet]. 2008;28(9):1614 - 20. http://view.ncbi.nlm.nih.gov/pubmed/18511699PDF Icon Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008 (738.26 KB)PDF Icon Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008, data supplement (1012.6 KB)
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, u. a.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522PDF Icon Caroline Heckman et al., Cancer Research 2008 (504.8 KB)
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, u. a.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522PDF Icon Caroline Heckman et al., Cancer Research 2008 (504.8 KB)

Seiten